Insilico Medicine published a study in Nature Biotechnology reporting that its AI-designed idiopathic pulmonary fibrosis candidate rentosertib produced reductions in predicted biological age.
The analysis used 12-week longitudinal Olink proteomic data from 42 patients enrolled in a Phase IIa trial and applied six independently developed proteomic aging clocks, all of which indicated biological age reversal in treated patients.
The trial also showed a dose-dependent improvement in forced vital capacity compared with placebo that the authors say aligned with the proteomic clock findings.
Rentosertib targets TNIK, an AI-identified gene implicated in six hallmarks of aging, and was designed with Insilico’s Chemistry42 platform; the program moved from target identification to preclinical candidate nomination in about 18 months.
Preclinical and Phase I results were published in 2024, Phase IIa findings were published in 2025, and rentosertib has entered Phase III development in China.
The work, conducted with collaborators at Harvard Medical School, Stanford, the Broad Institute, RWTH Aachen, Peking University and Westlake University, proposes a framework for embedding geroscience biomarkers into standard clinical trials.
